Evidence map›Paper›PMID 41772559›Full record

ArticleCardiovascular diabetology2026

Association of the C-reactive protein-triglyceride-glucose index with metabolic dysfunction-associated steatotic liver disease and long-term all-cause and cardiovascular mortality: evidence from two nationwide prospective cohort studies.

Xue-Feng Jin, Zhao-Jie Su, Jian-Fa Zhong, Jie Wang, Bao-Jie Shi, Zhen-Yu Liu, Ping-Sui Li, Xing Xiong, Shi-Quan Xu, Cheng Qiu and 18 more

Abstract read
In one paragraph

Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Xue-Feng Jin *Organ Transplantation Clinical Medical Centre of Xiamen University, Department of General Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China.
Zhao-Jie Su *Organ Transplantation Clinical Medical Centre of Xiamen University, Department of General Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China.
Jian-Fa Zhong *Organ Transplantation Clinical Medical Centre of Xiamen University, Department of General Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China.
Jie WangOrgan Transplantation Clinical Medical Centre of Xiamen University, Department of General Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China.
Bao-Jie ShiOrgan Transplantation Clinical Medical Centre of Xiamen University, Department of General Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China.
Zhen-Yu LiuOrgan Transplantation Clinical Medical Centre of Xiamen University, Department of General Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China.
Ping-Sui LiOrgan Transplantation Clinical Medical Centre of Xiamen University, Department of General Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China.
Xing XiongOrgan Transplantation Clinical Medical Centre of Xiamen University, Department of General Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China.
Shi-Quan XuOrgan Transplantation Clinical Medical Centre of Xiamen University, Department of General Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China.
Cheng QiuOrgan Transplantation Clinical Medical Centre of Xiamen University, Department of General Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China.
Yi XiaoOrgan Transplantation Clinical Medical Centre of Xiamen University, Department of General Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China.
Si-Bo LiDepartment of Haematology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361003, China.
Wen-Hui TongDepartment of Clinical Medicine, Nanjing University School of Clinical Medicine, Nanjing, Jiangsu, China.
Jing-Ping GeDepartment of Urology, Affiliated Taikang Xianlin Drum Tower Hospital, Medical School of Nanjing University, Nanjing, 210046, Jiangsu, China.
Hang-Xu LiDepartment of Urology, The Third Affiliated Hospital of Jinzhou Medical University, Jinzhou Medical University, Jinzhou, 121001, Liaoning, China.
Xiao-Yan LiuOutpatient Department of Fengtai, No. 10 Cadre Sanatorium for Retired Officers, Beijing Garrison District, Beijing, 100006, China.
Zi-Zhi LiDepartment of Urology, The Third Affiliated Hospital of Jinzhou Medical University, Jinzhou Medical University, Jinzhou, 121001, Liaoning, China.
Xiang-Rui KongDepartment of Urology, The Third Affiliated Hospital of Jinzhou Medical University, Jinzhou Medical University, Jinzhou, 121001, Liaoning, China.
Jun-Lin ChenDepartment of Urology, The Third Affiliated Hospital of Jinzhou Medical University, Jinzhou Medical University, Jinzhou, 121001, Liaoning, China.
Xue-Jiao WenDepartment of Urology, The Third Affiliated Hospital of Jinzhou Medical University, Jinzhou Medical University, Jinzhou, 121001, Liaoning, China.
Pan SunDepartment of Clinical Medicine, Nanjing University School of Clinical Medicine, Nanjing, Jiangsu, China.
Peng-Peng ChenDepartment of Medicine, Soochow University, Suzhou, 215000, Jiangsu, China.
Yang-Yang LiUniversity of Shanghai for Science and Technology, Oriental Academy of Innovation for Pan-vascular Devices, Shanghai, 200093, China.
Yang ChenJiangsu University School of Medicine, Zhenjiang, 212000, Jiangsu, China.
Lan-Tian MaoNanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu, China.
Zhi-Hai PengOrgan Transplantation Clinical Medical Centre of Xiamen University, Department of General Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China. pengzhihai1958@163.com.
Hao LiOrgan Transplantation Clinical Medical Centre of Xiamen University, Department of General Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China. lihao6656@163.com.
Tong ZhangOrgan Transplantation Clinical Medical Centre of Xiamen University, Department of General Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China. zhangtong@xah.xmu.edu.cn.

Funding

National Natural Science Foundation of China 82370669, 82201964
6 · The paper itself

Abstract

backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to cardiometabolic disorders, and cardiovascular disease is the leading cause of death among affected individuals. Identifying simple biomarkers that capture metabolic-inflammatory burden and predict long-term mortality in MASLD remains a clinical priority. The C-reactive protein-triglyceride-glucose index (CTI) integrates inflammation, dyslipidaemia, and glycaemic status, but its relevance to MASLD and long-term mortality has not been fully elucidated.

methodsWe conducted a multi-stage investigation using two nationally representative cohorts from the United States and China. Cross-sectional associations between CTI and MASLD were assessed in the National Health and Nutrition Examination Survey (NHANES) and the China Health and Retirement Longitudinal Study (CHARLS). Prospective associations of CTI with cardiovascular and all-cause mortality among participants with MASLD were examined utilising multivariable Cox proportional hazards models, restricted cubic splines, threshold analyses, and competing risk models. Causal mediation analyses were performed to measure the mediating functions of diabetes, hypertension, and body mass index. Extensive sensitivity analyses using alternative MASLD definitions and analytic strategies were conducted to assess robustness. Results from NHANES were externally validated in CHARLS.

resultsHigher CTI levels were strongly and nonlinearly associated with the presence of MASLD in both cohorts. Among individuals with MASLD, elevated CTI was associated with significantly increased risks of all-cause and cardiovascular mortality. Each unit increase in CTI in NHANES was linked to a 57% increased risk of cardiovascular death (HR 1.57, 95% CI 1.24-1.99) and a 47% increased risk of all-cause death (hazard ratio [HR] 1.47, 95% confidence interval [CI] 1.28-1.69) in fully adjusted models. A pronounced threshold effect was observed, with mortality risk rising sharply once CTI exceeded approximately 5.6. Consistent associations with all-cause mortality were observed in CHARLS. Mediation analyses indicated that diabetes accounted for a substantial proportion of the association between CTI and mortality, whereas body mass index played a minimal mediating role.

conclusionsCTI is a robust metabolic-inflammatory marker associated with MASLD and long-term all-cause and cardiovascular mortality across diverse populations. The strong mediating role of diabetes underscores the central importance of glycaemic dysfunction in cardiometabolic risk. As a readily obtainable index, CTI may aid in cardiometabolic risk stratification among individuals with MASLD.

Indexed as

Blood GlucoseCardiovascular DiseasesC-Reactive ProteinInflammation MediatorsNon-alcoholic Fatty Liver DiseaseTriglyceridesAgedBiomarkersCause of DeathChinaCross-Sectional StudiesFemaleHumansLongitudinal StudiesMaleMiddle AgedBiomarkersBlood GlucoseC-Reactive ProteinInflammation MediatorsTriglyceridesAll-cause mortalityCardiometabolic riskCardiovascular mortalityComposite triglyceride–inflammation indexDiabetesMetabolic dysfunction-associated steatotic liver disease

Identifiers

PMID41772559
PMCPMC12961832

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.